Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) just unveiled an update.
Guangzhou Innogen Pharmaceutical Group has moved to convert all of its domestic unlisted shares into H shares, filing an application with the China Securities Regulatory Commission on 17 March 2026. The company plans to list these converted H shares for trading on the Main Board of the Hong Kong Stock Exchange once all necessary regulatory approvals and filings are obtained.
The proposed full circulation of H shares aims to unify the company’s share structure and potentially enhance liquidity and accessibility for investors in the Hong Kong market. Details of the implementation plan are not yet final, and the conversion remains subject to approvals from the CSRC, the Hong Kong Stock Exchange and other regulators, with the company cautioning shareholders and potential investors about trading its shares during this process.
The most recent analyst rating on (HK:2591) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H stock, see the HK:2591 Stock Forecast page.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong, operating through H shares on the Main Board of the Stock Exchange. The group is engaged in the development and commercialization of pharmaceutical products, serving domestic and international investors through its Hong Kong listing structure.
Average Trading Volume: 824,895
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$10.28B
For detailed information about 2591 stock, go to TipRanks’ Stock Analysis page.